Skip to main content
Erschienen in: Tumor Biology 10/2014

01.10.2014 | Research Article

MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1

verfasst von: Zhiguo Liu, Yuguang Liu, Lianling Li, Zhenkuan Xu, Baibin Bi, Yunyan Wang, Jian Yi Li

Erschienen in: Tumor Biology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

The aberrant expression of microRNAs (miRNAs) is always associated with tumor development and progression. Microvascular proliferation is one of the unique pathologic features of glioblastoma (GBM) . In this study, the microvasculature from GBM or normal brain tissue derived from neurosurgeries was purified and total RNA was isolated from purified microvasculature. The difference of miRNA expression profiles between glioblastoma microvasculature and normal brain capillaries was investigated. It was found that miR-7-5p in GBM microvessels was significantly reduced compared with that in normal brain capillaries. In the in vitro experiments, overexpression of miR-7-5p significantly inhibited human umbilical vein endothelial cell proliferation. Forced expression of miR-7-5p in human umbilical vein endothelial cells in vitro significantly reduced the protein level of RAF1 and repressed the activity of the luciferase, a reporter vector carrying the 3′-untranslated region of RAF1. These findings indicate that RAF1 is one of the miR-7-5p target genes. Furthermore, a significant inverse correlation between miR-7-5p expression and RAF1 protein level in GBM microvasculature was found. These data suggest that miR-7-5p functions as a tumor suppressor gene to regulate GBM microvascular endothelial cell proliferation potentially by targeting the RAF1 oncogene, implicating an important role for miR-7-5p in the pathogenesis of GBM. It may serve as a guide for the antitumor angiogenesis drug development.
Literatur
2.
Zurück zum Zitat Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMed Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMed
3.
Zurück zum Zitat Pasquinelli AE, Hunter S, Bracht J. MicroRNAs: a developing story. Curr Opin Genet Dev. 2005;15(2):200–5.CrossRefPubMed Pasquinelli AE, Hunter S, Bracht J. MicroRNAs: a developing story. Curr Opin Genet Dev. 2005;15(2):200–5.CrossRefPubMed
4.
Zurück zum Zitat Ahmed FE. Role of miRNA in carcinogenesis and biomarker selection: a methodological view. Expert Rev Mol Diagn. 2007;7(5):569–603.CrossRefPubMed Ahmed FE. Role of miRNA in carcinogenesis and biomarker selection: a methodological view. Expert Rev Mol Diagn. 2007;7(5):569–603.CrossRefPubMed
5.
Zurück zum Zitat Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122 (1) :6–7. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122 (1) :6–7.
6.
8.
Zurück zum Zitat Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60(3):166–93. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60(3):166–93.
9.
Zurück zum Zitat Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol. 2001;101(4):311–20. Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol. 2001;101(4):311–20.
10.
Zurück zum Zitat Fuller GN, The WHO. Classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med. 2008;132(6):906.PubMed Fuller GN, The WHO. Classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med. 2008;132(6):906.PubMed
11.
Zurück zum Zitat Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8.CrossRef Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8.CrossRef
12.
Zurück zum Zitat Zhang C, Li C, Li J, Han J, Shang D, Zhang Y, et al. Identification of miRNA-mediated core gene module for glioma patient prediction by integrating high-throughput miRNA, mRNA expression and pathway structure. PLoS One. 2014;9(5):e96908. Zhang C, Li C, Li J, Han J, Shang D, Zhang Y, et al. Identification of miRNA-mediated core gene module for glioma patient prediction by integrating high-throughput miRNA, mRNA expression and pathway structure. PLoS One. 2014;9(5):e96908.
13.
Zurück zum Zitat Li JY, Boado RJ, Pardridge WM. Blood–brain barrier genomics. J Cereb Blood Flow Metab. 2001;21(1):61–8.CrossRefPubMed Li JY, Boado RJ, Pardridge WM. Blood–brain barrier genomics. J Cereb Blood Flow Metab. 2001;21(1):61–8.CrossRefPubMed
14.
Zurück zum Zitat Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, Purow B. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008; 68 (10) :3566–3572 Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, Purow B. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008; 68 (10) :3566–3572
15.
Zurück zum Zitat Kyriakis JM. The integration of signaling by multiprotein complexes containing Raf kinases. Biochim Biophys Acta. 2007;1773(8):1238–47.CrossRefPubMed Kyriakis JM. The integration of signaling by multiprotein complexes containing Raf kinases. Biochim Biophys Acta. 2007;1773(8):1238–47.CrossRefPubMed
16.
Zurück zum Zitat Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M, et al. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta. 2007;1773(8):1196–212. Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M, et al. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta. 2007;1773(8):1196–212.
17.
Zurück zum Zitat McPhillips F, Mullen P, MacLeod KG, Sewell JM, Monia BP, Cameron DA, et al. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis. 2006;27(4):729–39. McPhillips F, Mullen P, MacLeod KG, Sewell JM, Monia BP, Cameron DA, et al. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis. 2006;27(4):729–39.
18.
Zurück zum Zitat Zebisch A, Troppmair J. Back to the roots: the remarkable RAF oncogene story. Cell Mol Life Sci. 2006;63(11):1314–30.CrossRefPubMed Zebisch A, Troppmair J. Back to the roots: the remarkable RAF oncogene story. Cell Mol Life Sci. 2006;63(11):1314–30.CrossRefPubMed
19.
Zurück zum Zitat Pal A, Ahmad A, Khan S, Sakabe I, Zhang C, Kasid UN, et al. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol. 2005;26(4):1087–91. Pal A, Ahmad A, Khan S, Sakabe I, Zhang C, Kasid UN, et al. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol. 2005;26(4):1087–91.
20.
Zurück zum Zitat Fushimi K, Nakashima S, You F, Takigawa M, Shimizu K. Prostaglandin E2 downregulates TNF-alpha-induced production of matrix metalloproteinase-1 in HCS-2/8 chondrocytes by inhibiting Raf-1/MEK/ERK cascade through EP4 prostanoid receptor activation. J Cell Biochem. 2007;100(3):783–93. Fushimi K, Nakashima S, You F, Takigawa M, Shimizu K. Prostaglandin E2 downregulates TNF-alpha-induced production of matrix metalloproteinase-1 in HCS-2/8 chondrocytes by inhibiting Raf-1/MEK/ERK cascade through EP4 prostanoid receptor activation. J Cell Biochem. 2007;100(3):783–93.
21.
Zurück zum Zitat von Kriegsheim A, Pitt A, Grindlay GJ, Kolch W, Dhillon AS. Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5. Nat Cell Biol. 2006;8(9):1011–6.CrossRef von Kriegsheim A, Pitt A, Grindlay GJ, Kolch W, Dhillon AS. Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5. Nat Cell Biol. 2006;8(9):1011–6.CrossRef
22.
Zurück zum Zitat von B, V, Dubben S, Engelhardt G, Hebel S, Plumakers B, Heine H, Rink L, Haase H. Zinc-dependent suppression of TNF-alpha production is mediated by protein kinase A-induced inhibition of Raf-1 , I kappa B kinase beta, and NF-kappa B. J Immunol 2007; 179 (6) :4180–4186 von B, V, Dubben S, Engelhardt G, Hebel S, Plumakers B, Heine H, Rink L, Haase H. Zinc-dependent suppression of TNF-alpha production is mediated by protein kinase A-induced inhibition of Raf-1 , I kappa B kinase beta, and NF-kappa B. J Immunol 2007; 179 (6) :4180–4186
23.
Zurück zum Zitat Li Y, Levesque LO, Anand-Srivastava MB. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol. 2010;299(6):H1959–67.CrossRefPubMed Li Y, Levesque LO, Anand-Srivastava MB. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol. 2010;299(6):H1959–67.CrossRefPubMed
24.
Zurück zum Zitat Maretzky T, Evers A, Zhou W, Swendeman SL, Wong PM, Rafii S, et al. Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat Commun. 2011;2:229. Maretzky T, Evers A, Zhou W, Swendeman SL, Wong PM, Rafii S, et al. Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat Commun. 2011;2:229.
25.
Zurück zum Zitat Kyriakakis E, Cavallari M, Pfaff D, Fabbro D, Mestan J, Philippova M, et al. IL-8-mediated angiogenic responses of endothelial cells to lipid antigen activation of iNKT cells depend on EGFR transactivation. J Leukoc Biol. 2011;90(5):929–39. Kyriakakis E, Cavallari M, Pfaff D, Fabbro D, Mestan J, Philippova M, et al. IL-8-mediated angiogenic responses of endothelial cells to lipid antigen activation of iNKT cells depend on EGFR transactivation. J Leukoc Biol. 2011;90(5):929–39.
26.
Zurück zum Zitat Guang-Wu H, Sunagawa M, Jie-En L, Shimada S, Gang Z, Tokeshi Y, et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope. 2000;110(12):2066–9. Guang-Wu H, Sunagawa M, Jie-En L, Shimada S, Gang Z, Tokeshi Y, et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope. 2000;110(12):2066–9.
28.
Zurück zum Zitat Chen Y, Rabson AB, Gorski DH. MEOX2 regulates nuclear factor-kappaB activity in vascular endothelial cells through interactions with p65 and IkappaBbeta. Cardiovasc Res. 2010;87(4):723–31.CrossRefPubMedPubMedCentral Chen Y, Rabson AB, Gorski DH. MEOX2 regulates nuclear factor-kappaB activity in vascular endothelial cells through interactions with p65 and IkappaBbeta. Cardiovasc Res. 2010;87(4):723–31.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Chiplunkar AR, Curtis BC, Eades GL, Kane MS, Fox SJ, Haar JL, et al. The Kruppel-like factor 2 and Kruppel-like factor 4 genes interact to maintain endothelial integrity in mouse embryonic vasculogenesis. BMC Dev Biol. 2013;13:40. Chiplunkar AR, Curtis BC, Eades GL, Kane MS, Fox SJ, Haar JL, et al. The Kruppel-like factor 2 and Kruppel-like factor 4 genes interact to maintain endothelial integrity in mouse embryonic vasculogenesis. BMC Dev Biol. 2013;13:40.
30.
Zurück zum Zitat Zhang Y, Chen N, Zhang J, Tong Y. Hsa-let-7 g miRNA targets caspase-3 and inhibits the apoptosis induced by ox-LDL in endothelial cells. Int J Mol Sci. 2013;14(11):22708–20.CrossRefPubMedPubMedCentral Zhang Y, Chen N, Zhang J, Tong Y. Hsa-let-7 g miRNA targets caspase-3 and inhibits the apoptosis induced by ox-LDL in endothelial cells. Int J Mol Sci. 2013;14(11):22708–20.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Lee JY, et al. Absence of JAK2 V617F mutation in gastric cancers. Acta Oncol. 2006;45(2):222–3. Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Lee JY, et al. Absence of JAK2 V617F mutation in gastric cancers. Acta Oncol. 2006;45(2):222–3.
32.
Zurück zum Zitat Orom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene. 2006;372:137–41.CrossRefPubMed Orom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene. 2006;372:137–41.CrossRefPubMed
Metadaten
Titel
MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1
verfasst von
Zhiguo Liu
Yuguang Liu
Lianling Li
Zhenkuan Xu
Baibin Bi
Yunyan Wang
Jian Yi Li
Publikationsdatum
01.10.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 10/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2318-x

Weitere Artikel der Ausgabe 10/2014

Tumor Biology 10/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.